ES2095086T3 - Metodo para el tratamiento y la prevencion de la obesidad. - Google Patents

Metodo para el tratamiento y la prevencion de la obesidad.

Info

Publication number
ES2095086T3
ES2095086T3 ES93925058T ES93925058T ES2095086T3 ES 2095086 T3 ES2095086 T3 ES 2095086T3 ES 93925058 T ES93925058 T ES 93925058T ES 93925058 T ES93925058 T ES 93925058T ES 2095086 T3 ES2095086 T3 ES 2095086T3
Authority
ES
Spain
Prior art keywords
obesity
continue
prevention
treatment
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93925058T
Other languages
English (en)
Inventor
Ross G Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2095086T3 publication Critical patent/ES2095086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA TRATAR MAMIFEROS OBESOS O PREVENIR LA OBESIDAD QUE SUCEDE EN MAMIFEROS. ESTE METODO IMPLICA LA ADMINISTRACION A UN MAMIFERO DE UNA CANTIDAD EFECTIVA DE HORMONA DEL CRECIMIENTO EN COMBINACION CON UNA CANTIDAD EFECTIVA DE IGF - 1. PREFERIBLEMENTE, LA HORMONA DEL CRECIMIENTO SE LLEVA A ALCANZAR UNA PRESENCIA EFECTIVA, QUE SE MANTIENE TERAPEUTICAMENTE CONTINUA EN LA SANGRE, BIEN SEA POR MEDIO DE INFUSIONES CONTINUAS O INYECCIONES FRECUENTES, O POR MEDIO DEL EMPLEO DE FORMULACIONES DE ACTUACION PROLONGADA.
ES93925058T 1992-10-29 1993-10-26 Metodo para el tratamiento y la prevencion de la obesidad. Expired - Lifetime ES2095086T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96862392A 1992-10-29 1992-10-29

Publications (1)

Publication Number Publication Date
ES2095086T3 true ES2095086T3 (es) 1997-02-01

Family

ID=25514516

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93925058T Expired - Lifetime ES2095086T3 (es) 1992-10-29 1993-10-26 Metodo para el tratamiento y la prevencion de la obesidad.

Country Status (13)

Country Link
EP (1) EP0669832B1 (es)
JP (1) JPH08502969A (es)
AT (1) ATE143267T1 (es)
AU (1) AU675996B2 (es)
CA (1) CA2145501C (es)
DE (1) DE69305091T2 (es)
DK (1) DK0669832T3 (es)
ES (1) ES2095086T3 (es)
GR (1) GR3022074T3 (es)
LV (1) LV11987B (es)
MD (1) MD1486G2 (es)
TJ (1) TJ286B (es)
WO (1) WO1994009813A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW318226B (es) * 1995-05-11 1997-10-21 Sega Enterprises Kk
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
JP2002526417A (ja) * 1998-10-02 2002-08-20 セルトリックス ファーマシューティカルズ，インコーポレイテッド 非甲状腺性疾患の治療方法
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005020898A2 (en) 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
RU2317118C1 (ru) * 2006-09-21 2008-02-20 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения липодистрофии у больных сахарным диабетом
WO2023004687A1 (zh) * 2021-07-29 2023-02-02 浙江新码生物医药有限公司 一种非天然氨基酸及其应用、包含其的重组蛋白以及重组蛋白偶联物
AU2021458069B2 (en) * 2021-07-29 2025-04-24 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
AU5451294A (en) 1994-05-24
ATE143267T1 (de) 1996-10-15
CA2145501C (en) 2004-08-10
DE69305091T2 (de) 1997-03-13
AU675996B2 (en) 1997-02-27
WO1994009813A1 (en) 1994-05-11
DK0669832T3 (da) 1997-03-17
MD1486G2 (ro) 2001-11-30
EP0669832A1 (en) 1995-09-06
MD1486F2 (en) 2000-06-30
LV11987B (en) 1998-06-20
CA2145501A1 (en) 1994-05-11
DE69305091D1 (de) 1996-10-31
LV11987A (lv) 1998-03-20
EP0669832B1 (en) 1996-09-25
JPH08502969A (ja) 1996-04-02
TJ286B (en) 2000-12-13
MD960245A (en) 1997-12-31
GR3022074T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
ES2162393T3 (es) Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
ATE187321T1 (de) Absorbierender artikel mit kontrollierter flüssigkeitsverteilung
ES2154299T3 (es) Metodos para la regulacion de la motilidad gastrointestinal.
ES2177637T3 (es) Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.
YU132688A (en) Therapeutical system, which is effective through skin
ATE141799T1 (de) Die kombination des wachshormons und des insulin- ähnlichen wachstumsfaktors-i stimuliert das wachstum
ATE260051T1 (de) Verwendung von zusammensetzungen zur versorgung mit mineralien nach einer gastrotomie
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
AU1795101A (en) Safety mechanism to prevent accidental patient injection and methods of same
BR9405404A (pt) Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação
TJ286B (en) A method for treatment or prevention of obesity
CO5280195A1 (es) Combinaciones sinteticas de un antagonista de receptor de nk, y un analalogo estructural de gaba
DE69634662D1 (de) Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
DK0681631T3 (da) Vandlåsindretning og toiletkumme med en sådan indretning
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
AU7937691A (en) Parathyroid hypertensive factor
EP0797994A3 (en) Use of one or more 5-HT2 receptor antagonists in the manufacture of a medicament for treating the symptoms of venomous bites and stings
KR930702016A (ko) 골다공증 치료제
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
SG49645A1 (en) A method of treating liver disease and like indications with vasodilating agents
KR940003550A (ko) 노인성 치매 예방 및 치료방법
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
MD1610G2 (ro) Metodă de tratament al stomatitei aftoase recidivante cronice

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669832

Country of ref document: ES